Last reviewed · How we verify
METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE SODIUM SUCCINATE is a drug. It is currently FDA-approved (first approved 1959).
At a glance
| Generic name | METHYLPREDNISOLONE SODIUM SUCCINATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
Common side effects
- Fluid retention
- Increased appetite
- Nausea
- Headache
- Insomnia
- Mood swings
- Weight gain
- Moon face
- Acne
- Increased sweating
- Hirsutism
- Hypertension
Serious adverse events
- Anaphylaxis
- Cardiac arrest
- Circulatory collapse
- Myocardial rupture following recent myocardial infarction
- Peptic ulcer with possible perforation and hemorrhage
- Perforation of the small and large intestine
- Aseptic necrosis of femoral and humeral heads
- Convulsions
- Increased intracranial pressure with papilledema
- Arachnoiditis
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- METHYLPREDNISOLONE SODIUM SUCCINATE CI brief — competitive landscape report
- METHYLPREDNISOLONE SODIUM SUCCINATE updates RSS · CI watch RSS
Frequently asked questions about METHYLPREDNISOLONE SODIUM SUCCINATE
What is METHYLPREDNISOLONE SODIUM SUCCINATE?
METHYLPREDNISOLONE SODIUM SUCCINATE is a Small molecule drug.
When was METHYLPREDNISOLONE SODIUM SUCCINATE approved?
METHYLPREDNISOLONE SODIUM SUCCINATE was first approved on 1959.
What development phase is METHYLPREDNISOLONE SODIUM SUCCINATE in?
METHYLPREDNISOLONE SODIUM SUCCINATE is FDA-approved (marketed).
What are the side effects of METHYLPREDNISOLONE SODIUM SUCCINATE?
Common side effects of METHYLPREDNISOLONE SODIUM SUCCINATE include Fluid retention, Increased appetite, Nausea, Headache, Insomnia, Mood swings. Serious adverse events: Anaphylaxis, Cardiac arrest, Circulatory collapse, Myocardial rupture following recent myocardial infarction.